This is not the most recent version of the article. View current version (19 JUL 2006)

Intervention Protocol

You have free access to this content

Fish oil and other prostaglandin precursor supplementation during pregnancy for reducing pre-eclampsia, preterm birth, low birth weight and intrauterine growth restriction

  1. M Makrides,
  2. L Duley,
  3. SF Olsen

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 23 OCT 2001

DOI: 10.1002/14651858.CD003402


How to Cite

Makrides M, Duley L, Olsen SF. Fish oil and other prostaglandin precursor supplementation during pregnancy for reducing pre-eclampsia, preterm birth, low birth weight and intrauterine growth restriction (Protocol). The Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD003402. DOI: 10.1002/14651858.CD003402.

Author Information

*Dr Maria Makrides, Head, Applied Nutrition Group, Child Health Research Institute, Women's & Children's Hospital, 72 King William Road, North Adelaide, SA, 5006, AUSTRALIA. maria.makrides@cywhs.sa.gov.au.

Publication History

  1. Published Online: 23 OCT 2001

SEARCH

This is not the most recent version of the article. View current version (19 JUL 2006)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To estimate the effects of fish oil supplementation during pregnancy on the relative risk of pre-eclampsia, preterm birth, low birth weight and small for gestational age (SGA), as well as other substantive measures of maternal morbidity, and of morbidity and mortality for the child.

The effect, if any, on pre-eclampsia, preterm birth (delivery < 37 weeks), low birth weight (< 2500g), SGA (< 10th percentile) and perinatal death will be assessed to estimate whether it is influenced by whether:

1. Trial entry was before or after 16 weeks gestation.
2. High or low dietary fish intake before trial entry.
3. Supplementation was with fish oil or other prostaglandin precursors.
4. A placebo was used.
5. High or low/moderate risk of pre-eclampsia, preterm birth or intra-uterine growth restriction.

When sufficient data are available, later versions of the review will consider sub-group analysis based on singleton or multiple pregnancy.